Albany Molecular Research Incorporated operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Albany Molecular Research Incorporated with three other
companies in this sector in the United States:
Galapagos NV
(2012
sales of $197.46 million
of which 55%
was R&D),
Incyte Corp.
($297.06 million
of which 100%
was Drug Discovery & Development), and
Luminex Corporation
($202.58 million
of which 60%
was Technogy Group).
Sales Analysis.
Albany Molecular Research Incorporated reported sales of $226.69 million
for the
year ending
December of 2012.
This
represents
an
increase of 9.2%
versus 2011, when the company's sales were $207.65 million.
This was the third consecutive year of growth at Albany Molecular Research Incorporated.
Sales of Lsm saw an increase
that was more than double the company's growth rate: sales were up
26.8% in 2012, from
$95.58 million to $121.19 million.
Not all segments of Albany Molecular Research Incorporated experienced an increase in sales in 2012:
sales of Dds fell 5.9% to $105.50 million.
Business Description